JP2023525120A5 - - Google Patents

Info

Publication number
JP2023525120A5
JP2023525120A5 JP2022568760A JP2022568760A JP2023525120A5 JP 2023525120 A5 JP2023525120 A5 JP 2023525120A5 JP 2022568760 A JP2022568760 A JP 2022568760A JP 2022568760 A JP2022568760 A JP 2022568760A JP 2023525120 A5 JP2023525120 A5 JP 2023525120A5
Authority
JP
Japan
Prior art keywords
cancer
sequence
pharmaceutical composition
seq
adc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022568760A
Other languages
English (en)
Japanese (ja)
Other versions
JP7407973B2 (ja
JP2023525120A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/093348 external-priority patent/WO2021228141A1/zh
Publication of JP2023525120A publication Critical patent/JP2023525120A/ja
Publication of JP2023525120A5 publication Critical patent/JP2023525120A5/ja
Priority to JP2023213677A priority Critical patent/JP7734178B2/ja
Application granted granted Critical
Publication of JP7407973B2 publication Critical patent/JP7407973B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022568760A 2020-05-15 2021-05-12 抗体薬物複合体、その調製方法、およびその使用 Active JP7407973B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023213677A JP7734178B2 (ja) 2020-05-15 2023-12-19 抗体薬物複合体、その調製方法、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010410633.5 2020-05-15
CN202010410633 2020-05-15
PCT/CN2021/093348 WO2021228141A1 (zh) 2020-05-15 2021-05-12 抗体药物缀合物及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023213677A Division JP7734178B2 (ja) 2020-05-15 2023-12-19 抗体薬物複合体、その調製方法、およびその使用

Publications (3)

Publication Number Publication Date
JP2023525120A JP2023525120A (ja) 2023-06-14
JP2023525120A5 true JP2023525120A5 (cg-RX-API-DMAC7.html) 2023-08-15
JP7407973B2 JP7407973B2 (ja) 2024-01-04

Family

ID=78525267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022568760A Active JP7407973B2 (ja) 2020-05-15 2021-05-12 抗体薬物複合体、その調製方法、およびその使用
JP2023213677A Active JP7734178B2 (ja) 2020-05-15 2023-12-19 抗体薬物複合体、その調製方法、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023213677A Active JP7734178B2 (ja) 2020-05-15 2023-12-19 抗体薬物複合体、その調製方法、およびその使用

Country Status (18)

Country Link
US (1) US20230338565A1 (cg-RX-API-DMAC7.html)
EP (1) EP4151235A4 (cg-RX-API-DMAC7.html)
JP (2) JP7407973B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230012000A (cg-RX-API-DMAC7.html)
CN (1) CN115715202B (cg-RX-API-DMAC7.html)
AU (1) AU2021270940A1 (cg-RX-API-DMAC7.html)
CA (1) CA3178406A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022003170A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022016208A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220580A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000251A (cg-RX-API-DMAC7.html)
EC (1) ECSP22089507A (cg-RX-API-DMAC7.html)
GE (2) GEP20257719B (cg-RX-API-DMAC7.html)
IL (1) IL298184A (cg-RX-API-DMAC7.html)
JO (1) JOP20220306A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022014332A (cg-RX-API-DMAC7.html)
PE (1) PE20230373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021228141A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022402783A1 (en) * 2021-12-02 2024-06-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Method for preparing drug-linker conjugate
WO2023143208A1 (zh) * 2022-01-26 2023-08-03 苏州宜联生物医药有限公司 一种药物连接体偶联物的制备方法
CN119486763A (zh) * 2022-07-14 2025-02-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
JP2025527263A (ja) * 2022-08-02 2025-08-20 ノナ・バイオサイエンシズ(スーチョウ)カンパニー,リミテッド Msln抗体-薬物コンジュゲート
EP4623936A1 (en) 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2024175042A1 (zh) * 2023-02-24 2024-08-29 四川科伦博泰生物医药股份有限公司 药物偶联物治疗肿瘤疾病的用途及方法
EP4673475A1 (en) * 2023-03-02 2026-01-07 Multitude Therapeutics Inc. Antibody-drug conjugates, pharmaceutical compositions and uses thereof
AU2024263367A1 (en) * 2023-04-27 2025-11-13 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate
WO2024222841A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
EP4461317A1 (en) * 2023-05-12 2024-11-13 Emergence Therapeutics GmbH Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
JP2026521546A (ja) * 2023-06-16 2026-06-30 フォートビタ バイオロジクス(シンガポール)プライベート リミティド Claudin 18.2を標的とした抗体薬物複合体による固形腫瘍の治療方法
CN117327182B (zh) * 2023-09-19 2024-06-04 上海交通大学医学院附属仁济医院 Cldn18.2单域抗体探针的制备方法及应用
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2026086855A1 (zh) * 2024-10-25 2026-04-30 石药集团巨石生物制药有限公司 一种靶向cdcp1的抗体药物偶联物及其用途
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US9056092B2 (en) 2011-12-02 2015-06-16 Ethicon, Inc. Hemostatic bioabsorbable device with polyethylene glycol binder
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN111447939B (zh) * 2018-01-30 2024-07-12 四川科伦博泰生物医药股份有限公司 制备偶联物的方法
CN111542324B (zh) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
CA3087423A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN111110862A (zh) * 2018-11-01 2020-05-08 上海健信生物医药科技有限公司 抗cldn18.2抗体的药物偶联体及其制备方法和用途
EP3824096A4 (en) * 2018-07-18 2022-04-20 AskGene Pharma Inc. NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
KR20210109520A (ko) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
WO2021237717A1 (zh) * 2020-05-29 2021-12-02 武汉友芝友生物制药有限公司 抗cldn18.2和cd3的双特异性抗体

Similar Documents

Publication Publication Date Title
JP2023539715A5 (cg-RX-API-DMAC7.html)
JP2023542066A5 (cg-RX-API-DMAC7.html)
JP2023545096A5 (cg-RX-API-DMAC7.html)
JP2022095908A5 (cg-RX-API-DMAC7.html)
JP2024153803A5 (cg-RX-API-DMAC7.html)
JP2024543508A5 (cg-RX-API-DMAC7.html)
JP2020019787A5 (cg-RX-API-DMAC7.html)
JP2020529863A5 (cg-RX-API-DMAC7.html)
JP2019532056A5 (cg-RX-API-DMAC7.html)
JP2023527962A5 (cg-RX-API-DMAC7.html)
JP2021513541A5 (cg-RX-API-DMAC7.html)
JP2018537975A5 (cg-RX-API-DMAC7.html)
JP2009505676A5 (cg-RX-API-DMAC7.html)
JP2023542065A5 (cg-RX-API-DMAC7.html)
JP2025092589A5 (cg-RX-API-DMAC7.html)
JP2026504636A5 (cg-RX-API-DMAC7.html)
RU2018122629A (ru) Антитела против 5t4 и конъюгаты антитело-лекарственное средство
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2019524714A5 (cg-RX-API-DMAC7.html)
JP2025507817A5 (cg-RX-API-DMAC7.html)
JP2023514167A5 (cg-RX-API-DMAC7.html)
JP2023509214A5 (cg-RX-API-DMAC7.html)
JP2020529862A5 (cg-RX-API-DMAC7.html)
JPWO2022270524A5 (cg-RX-API-DMAC7.html)
JP2024523422A5 (cg-RX-API-DMAC7.html)